DelveInsight’s ‘Obstructive Sleep Apnea Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline Obstructive Sleep Apnea therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Obstructive Sleep Apnea pipeline domain.

Obstructive Sleep Apnea Overview

Obstructive Sleep Apnea is a sleep- related breathing disorder in which there is repeated obstruction to the upper airway, while the person is sleeping. Obstructive sleep apnea is when something blocks part or all of the upper airway while a person is asleep. The diaphragm and chest muscles have to work harder to open the airway and pull air lungs. 

Some of the key takeaways from the Obstructive Sleep Apnea Pipeline Report:

• Companies across the globe are diligently working toward developing novel Obstructive Sleep Apnea treatment therapies with a considerable amount of success over the years. Obstructive Sleep Apnea Key players such as – Apnimed, Desitin Arzneimittel GmbH, Eli Lilly and Company, Bayer, Takeda, Taisho Pharmaceutical Co., Ltd., and others, are developing therapies for the Obstructive Sleep Apnea treatment 
• Obstructive Sleep Apnea Emerging therapies such as – BAY 2586116, TS-142, AD-109, TAK-925, Sulthiame, Tirzepatide, and others are expected to have a significant impact on the Obstructive Sleep Apnea market in the coming years.
• In June 2022, Eli Lilly and Company initiated a trial titled, “A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial’.
• In July 2022, Eli Lilly Japan K.K. and Mitsubishi Tanabe Pharma Corporation announced that the two companies signed a sales collaboration agreement in Japan for Tirzepatide, which is under development by Eli Lilly Japan.

Discover more about the emerging Obstructive Sleep Apnea drugs @ Obstructive Sleep Apnea Treatment Drugs

Emerging Obstructive Sleep Apnea Drugs Under Different Phases of Clinical Development Include: 

• TS-142: Taisho Pharmaceutical Co., Ltd
• TAK-925: Takeda
• Tirzepatide: Eli Lilly and Company
• AD-109: Apnimed
• BAY 2586116: Bayer
• Sulthiame: Desitin Arzneimittel GmbH

 

Obstructive Sleep Apnea Pipeline Analysis:

The Obstructive Sleep Apnea pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Obstructive Sleep Apnea treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obstructive Sleep Apnea Treatment.
• Obstructive Sleep Apnea key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Obstructive Sleep Apnea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obstructive Sleep Apnea market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Obstructive Sleep Apnea Market Drivers 

• Increase in Obstructive Sleep Apnea prevalence
• Rising Obstructive Sleep Apnea awareness

Obstructive Sleep Apnea Market Barriers

• Lack of approved Obstructive Sleep Apnea drugs
• Complexity of Obstructive Sleep Apnea pathogenesis

Find out more about the Obstructive Sleep Apnea treatment options in development @ Obstructive Sleep Apnea Clinical Trials

Scope of Obstructive Sleep Apnea Pipeline Drug Insight    

• Coverage: Global
• Key Obstructive Sleep Apnea Companies: Apnimed, Desitin Arzneimittel GmbH, Eli Lilly and Company, Bayer, Takeda, Taisho Pharmaceutical Co., Ltd. , and others
• Key Obstructive Sleep Apnea Therapies: BAY 2586116, TS-142, AD-109, TAK-925, Sulthiame, Tirzepatide, and others
• Obstructive Sleep Apnea Therapeutic Assessment: Obstructive Sleep Apnea current marketed and Obstructive Sleep Apnea emerging therapies
• Obstructive Sleep Apnea Market Dynamics:  Obstructive Sleep Apnea market drivers and Obstructive Sleep Apnea market barriers 

Table of Contents

1. Introduction

2. Executive Summary

3. Obstructive Sleep Apnea Overview

4. Obstructive Sleep Apnea Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Obstructive Sleep Apnea Therapeutic Assessment

11. Obstructive Sleep Apnea Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Obstructive Sleep Apnea Unmet Needs

14. Obstructive Sleep Apnea Market Drivers and Obstructive Sleep Apnea Market Barriers

15. Appendix

16. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Navdha Goel
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com